NorthView Acquisition Corporation - Common Stock

NorthView Acquisition Corporation - Common Stock

Share · US66718N1037 · NVAC (XNAS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NorthView Acquisition Corporation - Common Stock
No Price
Share Float & Liquidity
Free Float 11,30 %
Shares Float 604.573,00
Shares Outstanding 5,35 M
Company Profile for NorthView Acquisition Corporation - Common Stock Share
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

Company Data

Name NorthView Acquisition Corporation - Common Stock
Company NorthView Acquisition Corporation
Symbol NVAC
Website https://www.northviewac.com
Primary Exchange XNAS NASDAQ
ISIN US66718N1037
Asset Class Share
Sector Financial Services
Industry Shell Companies
CEO Jack E. Stover CPA
Market Capitalization 13 Mio
Country United States of America
Currency USD
Employees -
Address 207 West 25th Street, 10001 New York City
IPO Date 2022-01-24

Ticker Symbols

Name Symbol
NASDAQ NVAC
More Shares
Investors who hold NorthView Acquisition Corporation - Common Stock also have the following shares in their portfolio:
DANSKE BK 20/28 FLR MTN
DANSKE BK 20/28 FLR MTN Bond
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Share